Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome

Journal of Alzheimer's Disease

Volumn 33, Issue 2, 2013, Pages 339-348

  Opattova, Alena ^a   Filipcik, Peter ^a,b   Cente, Martin ^a,b   Novak, Michal ^a,b  

^a INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

^b Axon Neuroscience SE ^*  (Slovakia)

Author keywords

Cellular model; geldanamycin; proteasome; protein tau

Indexed keywords

CHYMOTRYPSIN; GELDANAMYCIN; PROTEASOME; PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN UNFOLDING;

EID: 84872482226     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121072     Document Type: Article

References (38)

1. Novak M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12, 365-370. (Pubitemid 23042416)
2. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53-69.
3. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739, 198-210. (Pubitemid 40018538)
4. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study. Lancet Neurol 10, 785-796.
5. Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121, 171-181.
6. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, NovakM(2006) Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 580, 3582-3588. (Pubitemid 43902790)
7. Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M (2008) Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur J Neurosci 28, 239-246.
8. Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M (2012) First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging 33, 1448-1456.
9. Khlistunova I, Biernat J,WangY, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281, 1205-1214.
10. Bandyopadhyay B, Li G, Yin H, Kuret J (2007) Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 282, 16454-16464. (Pubitemid 47100356)
11. ZilkovaM, Zilka N,KovacA,Kovacech B, Skrabana R, Skrabanova M, Novak M (2011) Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model. J Alzheimers Dis 23, 161-169.
12. CiechanoverA(2005) Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 12, 1178-1190.
13. Dennissen FJ, Kholod N, van Leeuwen FW (2012) The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim? Prog Neurobiol 96, 190-207.
14. Rubinsztein DC (2006) The roles of intracellular proteindegradation pathways in neurodegeneration (Pubitemid 44622682)
15. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM,Wolozin B, Hardy J, HuttonM(2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13, 703-714. (Pubitemid 38455958)
16. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117, 648-658. (Pubitemid 46348523)
17. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G (2007) Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 104, 9511-9516. (Pubitemid 47185810)
18. Kruger U, Wang Y, Kumar S, Mandelkow EM (2012) Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 33, 2291-2305.
19. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
20. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4, 13.
21. Douglas PM, Dillin A (2010) Protein homeostasis and aging in neurodegeneration. J Cell Biol 190, 719-729.
22. Pritchard SM, Dolan PJ, Vitkus A, Johnson GV (2011) The toxicity of tau in Alzheimer disease: Turnover, targets and potential therapeutics. J Cell Mol Med 15, 1621-1635.
23. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
24. Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM (1996) Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol 91, 633-641. (Pubitemid 26166678)
25. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739, 216-223. (Pubitemid 40018540)
26. Novak M (1994) Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol 38, 173-189.
27. Cente M, Filipcik P, Pevalova M, NovakM(2006) Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy Eur J Neurosci 24, 1085-1090. (Pubitemid 44268139)
28. Dolan PJ, Johnson GV (2010) A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem 285, 21978-21987.
29. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum Mol Genet 18, 4153-4170.
30. David DC, Layfield R, Serpell L, Narain Y, Goedert M, SpillantiniMG(2002) Proteasomal degradation of tau protein J Neurochem 83, 176-185.
31. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332. (Pubitemid 39061125)
32. Yen SS (2011) Proteasome degradation of brain cytosolic tau in Alzheimer's disease. Int J Clin Exp Pathol 4, 385-402.
33. Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85, 115-122. (Pubitemid 36389701)
34. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H (2011) Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol 93, 99-110.
35. Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J (2009) Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis 17, 319-325.
36. Pajonk F, McBride WH (2001) The proteasome in cancer biology and treatment. Radiat Res 156, 447-459. (Pubitemid 33027513)
37. McLean PJ, Klucken J, Shin Y, Hyman BT (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321, 665-669. (Pubitemid 39127407)
38. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G (2006) Modulation of Hsp90 function in neurodegenerative disorders: Amolecular-targeted therapy against disease-causing protein. J Mol Med (Berl) 84, 635-646. (Pubitemid 44162553)